<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02470026</url>
  </required_header>
  <id_info>
    <org_study_id>KU3106/2-1</org_study_id>
    <nct_id>NCT02470026</nct_id>
  </id_info>
  <brief_title>Noradrenergic Activity, Cognition and Major Depressive Disorder</brief_title>
  <acronym>YohCog</acronym>
  <official_title>Influences on Noradrenergic Activity for Cognition in Patients With Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates influences of nordadrenergic activity on cognition in patients with
      major depression regarding influences of early life stress.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stress plays a major role in the development and maintenance of major depression disorder.
      Indeed, various studies demonstrated maladaptive changes in physiological stress regulation
      systems of depressive patients, i.e. in the hypothalamus-pituitary-adrenal axis and the locus
      coeruleus-noradrenergic system. On a central level, changes of the locus
      coeruleus-noradrenergic system have been demonstrated.This seems to be the case especially in
      depressive patients with early life traumata. Comparable to the
      hypothalamus-pituitary-adrenal axis, the locus coeruleus-noradrenergic system influences not
      only the physiological stress response, but has also central influence with effects on
      cognitive functions. Indeed, noradrenergic effects on cognitive functions such as attention,
      learning and memory have been demonstrated in healthy individuals. Even though deficits in
      cognitive domains are core symptoms of major depression, the relationship of the
      noradrenergic system and cognitive processes has rarely been investigated so far.

      In this project, the investigators will examine noradrenergic influences via administration
      of the alpha2-receptor blocker yohimbine on cognitive and emotionally relevant processes in
      depressive patients and controls. Additionally, the investigators will examine the influence
      of early life traumata on these relationships. Thus, the investigators will examine
      participants with and without major depression and with and without early life stress.

      Results of this study will improve the understanding of cognitive dysfunctions associated
      with the noradrenergic system in patients with major depression.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Actual">November 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>behavioral responses in two different conditions of noradrenergic stimulation</measure>
    <time_frame>2,5 hrs</time_frame>
    <description>reaction times and error scores (computer tasks)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>physiological responses in two different conditions of noradrenergic stimulation</measure>
    <time_frame>2,5 hrs</time_frame>
    <description>physiological recordings, saliva samples</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Major Depressive Disorder</condition>
  <condition>Early Life Trauma</condition>
  <arm_group>
    <arm_group_label>Yohimbine-Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single low dose treatment with yohimbine on test day 1, placebo on test day 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-Yohimbin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>placebo on test day 1, single low dose treatment with yohimbine on test day 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>yohimbine</intervention_name>
    <description>single low dose treatment</description>
    <arm_group_label>Yohimbine-Placebo</arm_group_label>
    <arm_group_label>Placebo-Yohimbin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>single control treatment</description>
    <arm_group_label>Yohimbine-Placebo</arm_group_label>
    <arm_group_label>Placebo-Yohimbin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of major depression

          -  experience of early life trauma

        Exclusion Criteria:

          -  severe illness

          -  Alzheimer´s

          -  schizophrenia

          -  bipolar disorder

          -  control group: - diagnosis of major depression/ experience of early life trauma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Linn K Kühl, PhD</last_name>
    <phone>+49 30 450-517625</phone>
    <email>linn.kuehl@charite.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Charite University</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linn K Kühl, PhD</last_name>
      <phone>+49 30 450-517625</phone>
      <email>linn.kuehl@charite.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2015</study_first_submitted>
  <study_first_submitted_qc>June 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2015</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Linn Kuehl, PhD</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Yohimbine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

